Progress to be made in asthma management
- PMID: 36669796
- DOI: 10.1016/S2214-109X(22)00551-4
Progress to be made in asthma management
Conflict of interest statement
MWP reports other support from Sanofi, AbbVie, and Novartis, outside the submitted work. IP reports other support from Sanofi and Regeneron Pharmaceuticals and non-financial support from Excerpta Medica, during the conduct of the study. IP also reports grants and other from Chiesi and other support from Aerocrine AB, Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals, Sanofi, Teva, Circassia, Dey Pharma, Genentech, Knopp Biosciences, Merck, Merck Sharp & Dohme, Napp Pharmaceuticals, RespiVert, and Schering-Plough, outside the submitted work.
Comment on
-
Asthma management and control in children, adolescents, and adults in 25 countries: a Global Asthma Network Phase I cross-sectional study.Lancet Glob Health. 2023 Feb;11(2):e218-e228. doi: 10.1016/S2214-109X(22)00506-X. Lancet Glob Health. 2023. PMID: 36669806 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical